share_log

康希諾生物：內幕消息 2023年年度業績預告

CANSINOBIO: INSIDE INFORMATION RESULTS FORECAST FOR THE YEAR 2023

香港交易所 ·  Jan 30 19:10
Summary by Futu AI
康希諾生物股份公司（「本公司」）發佈了2023年度業績預告，預計2023年全年將出現淨虧損，範圍在人民幣1,268.5百萬元至1,496.9百萬元之間。扣除非經常性損益後，預計淨虧損為人民幣1,377.0百萬元至1,624.9百萬元。該預告未經獨立核數師審計或審閱。與去年同期相比，淨虧損增加的主要原因是新冠疫苗市場需求下降，以及對新冠疫苗產品退回金額的核算與估計。此外，由於產能利用不足，公司對相關存貨和資產進行了減值測試並計提減值損失。儘管如此，公司流腦疫苗產品銷售收入有所增長。公司強調，這些數據僅為初步核算，具體財務數據將以經審計的年度報告為準。公告由董事長Xuefeng YU於2024年1月30日發佈。
康希諾生物股份公司（「本公司」）發佈了2023年度業績預告，預計2023年全年將出現淨虧損，範圍在人民幣1,268.5百萬元至1,496.9百萬元之間。扣除非經常性損益後，預計淨虧損為人民幣1,377.0百萬元至1,624.9百萬元。該預告未經獨立核數師審計或審閱。與去年同期相比，淨虧損增加的主要原因是新冠疫苗市場需求下降，以及對新冠疫苗產品退回金額的核算與估計。此外，由於產能利用不足，公司對相關存貨和資產進行了減值測試並計提減值損失。儘管如此，公司流腦疫苗產品銷售收入有所增長。公司強調，這些數據僅為初步核算，具體財務數據將以經審計的年度報告為準。公告由董事長Xuefeng YU於2024年1月30日發佈。
Consino Biologics Corporation (the “Company”) has announced its 2023 results forecast for a full-year 2023 net loss ranging from RMB 1,268.5 million to RMB 1,496.9 million. NET LOSS IS EXPECTED TO BE RMB1,377.0 MILLION TO $1,624.9 MILLION AFTER EXCLUDING NON-RECURRING LOSSES. The announcement has not been audited or reviewed by an independent auditor. The main reason for the increase in net loss compared to the same period last year was the decrease in the market demand for COVID-19 vaccines and the accounting and estimation of the refund amount for the COVID-19 vaccine product. In addition, due to insufficient capacity utilization, the company conducted depreciation tests on related inventories and assets and calculated depreciation losses. Despite this, the company's revenue from brain drain vaccine products grew. The company emphasizes that these data are preliminary estimates only, and specific financial data will be based on audited annual reports. The announcement was made by Chairman Xuefeng YU on January 30, 2024.
Consino Biologics Corporation (the “Company”) has announced its 2023 results forecast for a full-year 2023 net loss ranging from RMB 1,268.5 million to RMB 1,496.9 million. NET LOSS IS EXPECTED TO BE RMB1,377.0 MILLION TO $1,624.9 MILLION AFTER EXCLUDING NON-RECURRING LOSSES. The announcement has not been audited or reviewed by an independent auditor. The main reason for the increase in net loss compared to the same period last year was the decrease in the market demand for COVID-19 vaccines and the accounting and estimation of the refund amount for the COVID-19 vaccine product. In addition, due to insufficient capacity utilization, the company conducted depreciation tests on related inventories and assets and calculated depreciation losses. Despite this, the company's revenue from brain drain vaccine products grew. The company emphasizes that these data are preliminary estimates only, and specific financial data will be based on audited annual reports. The announcement was made by Chairman Xuefeng YU on January 30, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.